Pedro Barata

Pedro Barata

Tulane University

H-index: 24

North America-United States

Contact Pedro Barata

About Pedro Barata

Pedro Barata, With an exceptional h-index of 24 and a recent h-index of 24 (since 2020), a distinguished researcher at Tulane University, specializes in the field of Medical Oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor …

The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative …

Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.

Initial screening efforts for the OPTIC RCC trial.

Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC).

The influence of the germline HSD3B1 adrenal-permissive variant (c.1100 C) on somatic alteration landscape, transcriptome, and immune-cell infiltration in …

Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.

Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas

Pedro Barata Information

University	Tulane University
Position	Assistant Professor of Medicine
Citations(all)	2826
Citations(since 2020)	2646
Cited By	1035
hIndex(all)	24
hIndex(since 2020)	24
i10Index(all)	48
i10Index(since 2020)	46
Email	Access Email
University Profile Page	Tulane University
Google Scholar	View Google Scholar Profile

Pedro Barata Skills & Research Interests

Medical Oncology

Top articles of Pedro Barata

Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor …

2024/2/1

Dimitrios Makrakis

H-Index: 21

Leonidas Nikolaos Diamantopoulos

H-Index: 5

Vinay Mathew Thomas

H-Index: 4

Shilpa Gupta

H-Index: 53

Ali Raza Khaki

H-Index: 8

The impact of SPOP gene alterations in men with metastatic prostate cancer: Results from the Prostate Cancer Precision Medicine Multi-Institutional Collaborative …

2024/2/1

Nicholas Henderson

H-Index: 2

Mehmet Asim Bilen

H-Index: 21

Laura Graham

H-Index: 15

Rohan Garje

H-Index: 9

Abhishek Tripathi

H-Index: 17

Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.

2024/2/1

Soumyajit Roy

H-Index: 16

Christopher Sweeney

H-Index: 3

Yilun Sun

H-Index: 9

Initial screening efforts for the OPTIC RCC trial.

2024/2/1

Tian Zhang

H-Index: 1

Clinicogenomic characterization of patients with rapid tumor progression versus sustained response to frontline systemic therapy for metastatic urothelial carcinoma (mUC).

2024/2/1

Albert Jang

H-Index: 6

The influence of the germline HSD3B1 adrenal-permissive variant (c.1100 C) on somatic alteration landscape, transcriptome, and immune-cell infiltration in …

2024/2/1

Andrew Elliott

H-Index: 12

Nima Sharifi

H-Index: 1

Avelumab first-line maintenance therapy for locally advanced/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study.

2024/2/1

Shilpa Gupta

H-Index: 53

Jason Brown

H-Index: 11

Sarah Hanson

H-Index: 8

Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas

Modern Pathology

2024/2/1

Andrew Elliott

H-Index: 12

Pedro Barata

H-Index: 14

Pedram Argani

H-Index: 63

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness

The Prostate

2024/2

Mark Fleming

H-Index: 17

Roberto Pili

H-Index: 7

Alexandra Sokolova

H-Index: 5

Christina Tran

H-Index: 1

Rebecca Green

H-Index: 22

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Cancer Research Communications

2024/1/8

Natalie Slopen

H-Index: 36

Pedro Barata

H-Index: 14

Rebecca Green

H-Index: 22

Camille Ragin

H-Index: 23

Sebastien Haneuse

H-Index: 35

Evidence of Gender Disparities in Citations and Altmetric Attention Score in Oncology

medRxiv

2024

Maarten Albersen

H-Index: 26

Shilpa Gupta

H-Index: 53

Pedro Barata

H-Index: 14

Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons

2024/1

Albert Jang

H-Index: 6

Symptom Clusters in Patients With Advanced Cancer: A Prospective Longitudinal Cohort Study to Examine Their Stability and Prognostic Significance

The Oncologist

2024/1/1

MP68-16 REAL WORLD TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER STRATIFIED BY PRIOR NOVEL HORMONAL THERAPY AND TAXANE USE

The Journal of Urology

2024/5

Pedro Barata

H-Index: 14

Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles

The Journal of Clinical Investigation

2024/4/23

Pedro Barata

H-Index: 14

Shuchi Gulati

H-Index: 7

Andrew Elliott

H-Index: 12

Arnab Basu

H-Index: 6

Tian Zhang

H-Index: 1

CRE24-034: Successful Management of Locally Advanced and Oligometastatic Urothelial Carcinoma With Pembrolizumab-Based Induction Regimen Followed by Consolidative Radical …

Journal of the National Comprehensive Cancer Network: JNCCN

2024/4/5

Albert Jang

H-Index: 6

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable Alterations

JCO Precision Oncology

2024/4

Albert Jang

H-Index: 6

George Mo

H-Index: 0

Alexandra Sokolova

H-Index: 5

Abhishek Tripathi

H-Index: 17

Bicky Thapa

H-Index: 6

Rohan Garje

H-Index: 9

Marcin Cieslik

H-Index: 27

SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER …

Urologic Oncology: Seminars and Original Investigations

2024/3/1

Abhishek Tripathi

H-Index: 17

Pedro Barata

H-Index: 14

Alan Tan

H-Index: 10

Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Prostate Cancer and Prostatic Diseases

2024/2/28

Andrew Elliott

H-Index: 12

John R Lozada

H-Index: 8

Pedro Barata

H-Index: 14

Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration

Prostate Cancer and Prostatic Diseases

2024/2/22

Laura Graham

H-Index: 15

George Mo

H-Index: 0

Abhishek Tripathi

H-Index: 17

Rohan Garje

H-Index: 9

Ajjai Alva

H-Index: 29

See List of Professors in Pedro Barata University(Tulane University)

academic-engine

Useful Links

List of top 50 universities

List of top 100 universities

List of top 500 universities

Find Professors Email

Find Universities Email

CUFinder Academic Engine